FDA ap­proves Chiesi’s gel for rare skin dis­ease af­ter ini­tial 2022 re­jec­tion for Am­ryt

Cer­tain chil­dren with the rare skin dis­ease epi­der­mol­y­sis bul­losa now have a treat­ment op­tion thanks to an FDA ap­proval for Chiesi Glob­al Rare Dis­eases’ top­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER